Use of hydroxytyrosol acetate in improving function of aortic endothelial cell

Abstract

The present disclosure discloses use of hydroxytyrosol acetate in preparation of a medicament for improving aortic endothelial cell function. The hydroxytyrosol acetate is capable of inhibiting an inflammation of aortic endothelial cells caused by a saturated fatty acid, reducing mRNA levels corresponding to matrix metalloproteinase-1 (MMP-1), intercellular adhesion molecule-1 (ICAM-1) and plasma plasminogen activator inhibitor-1 (PAI-1) in aortic endothelial cells and protecting mitochondria from being damaged by inflammation of aortic endothelial cells caused by a saturated fatty acid, preventing the occurrence and development of atherosclerosis by anti-inflammatory and protecting mitochondrial function.

What is claimed is: 
     
         1 . A pharmaceutical composition for ameliorating aortic endothelial cell function, the pharmaceutical composition comprising hydroxytyrosol acetate. 
     
     
         2 . The pharmaceutical composition of  claim 1 , being medicine or a nutritional supplement. 
     
     
         3 . The pharmaceutical composition of  claim 1 , further comprising a pharmaceutical acceptable diluent, an excipient, or a carrier. 
     
     
         4 . The pharmaceutical composition of  claim 1 , wherein the hydroxytyrosol acetate is capable of inhibiting an inflammation of an aortic endothelial cell caused by a saturated fatty acid. 
     
     
         5 . The pharmaceutical composition of  claim 1 , wherein the hydroxytyrosol acetate is capable of reducing mRNA levels corresponding to matrix metalloproteinase-1 (MMP-1), intercellular adhesion molecule-1 (ICAM-1) and/or plasma plasminogen activator inhibitor-1 (PAI-1) in an aortic endothelial cell. 
     
     
         6 . The pharmaceutical composition of  claim 1 , wherein the hydroxytyrosol acetate is capable of reducing a mRNA level corresponding to interleukin 6 (IL-6) in an aortic endothelial cell. 
     
     
         7 . The pharmaceutical composition of  claim 1 , wherein the hydroxytyrosol acetate is capable of protecting mitochondria from being damaged by inflammation of an aortic endothelial cell caused by a saturated fatty acid. 
     
     
         8 . The pharmaceutical composition of  claim 1 , wherein the hydroxytyrosol acetate is capable of reducing a production of excessive reactive oxygen species in an aortic endothelial cell and increasing an expression of mitochondrial membrane fusion-related protein Mfn2 in the aortic endothelial cell. 
     
     
         9 . A method for preventing or treating a cardiovascular disease, the method comprising administering to a patient in need thereof a therapeutically effective amount of the pharmaceutical composition of  claim 1 . 
     
     
         10 . A method for preventing atherosclerosis, the method comprising administering to a patient in need thereof a therapeutically effective amount of the pharmaceutical composition of  claim 1 . 
     
     
         11 . A method for improving function of an aortic endothelial cell, the method comprising contacting the cell with an effective amount of hydroxytyrosol acetate. 
     
     
         12 . The method of  claim 11 , wherein the hydroxytyrosol acetate inhibits saturated fatty acid induced inflammation of an aortic endothelial cell. 
     
     
         13 . The method of  claim 11 , wherein the hydroxytyrosol acetate reduces a mRNA level corresponding to one or more of matrix metalloproteinase-1 (MMP-1), intercellular adhesion molecule-1 (ICAM-1) and plasma plasminogen activator inhibitor-1 (PAI-1) in an aortic endothelial cell. 
     
     
         14 . The method of  claim 11 , wherein the hydroxytyrosol acetate reduces a mRNA level corresponding to interleukin-6 (IL-6) in an aortic endothelial cell. 
     
     
         15 . The method of  claim 11 , wherein the hydroxytyrosol acetate protects a mitochondrion from being damaged by saturated fatty acid induced inflammation of an aortic endothelial cell. 
     
     
         16 . The method of  claim 11 , wherein the hydroxytyrosol acetate increases an expression of mitochondrial membrane fusion related protein Mfn2 in an aortic endothelial cell. 
     
     
         17 . The method of  claim 11 , wherein the hydroxytyrosol acetate reduces a production of excessive reactive oxygen species in an aortic endothelial cell. 
     
     
         18 . Use of hydroxytyrosol acetate in preparation of a medicament for improving aortic endothelial cell function. 
     
     
         19 . The use of  claim 18 , wherein the medicament is for preventing or treating a cardiovascular disease. 
     
     
         20 . The use of  claim 18 , wherein the medicament is for preventing or treating atherosclerosis.